RxDoctor Payments Data

Timothy Suttle, MD

Urology · Reno, NVNPI 1093039976

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (56.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 77.2% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $3,733, more than ten times the $116 reported in 2019.

$8,107in general payments, 2019–2025

Across 61 payments — averaging $132.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Boston Scientific$487
  • Calyxo, Inc.$263
  • Medtronic$181
  • Sumitomo Pharma America, Inc.$174
  • Astellas Pharma US Inc$132
  • plus $609 from 12 others

What the payments were for

  • Travel & lodging$1,42518%
  • Food & beverage$2,10226%
  • Education$4,58056%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,107 in reported general payments places this provider in the 60th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$215,416
Medicare patients
533
Services billed
2,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron30$26,016
MyrbetriqMirabegron11$10,770
Estradiol55$3,266
Tamsulosin Hcl135$2,474
Oxybutynin Chloride ErOxybutynin Chloride99$1,992
Finasteride65$1,531
CefuroximeCefuroxime Axetil94$1,236
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$472
Oxybutynin Chloride40$385
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$240
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$179
Oxycodone Hcl27$144
Fluconazole12$96
Levofloxacin11$56
Ciprofloxacin Hcl11$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$174$26,01630 claims
Astellas Pharma US IncMyrbetriq$132$10,77011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 63 urology providers in Nevada.

Other urology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →